Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conjugate Addition (1,4-Addition) vs Direct Addition (1,2-Addition)01:27

Conjugate Addition (1,4-Addition) vs Direct Addition (1,2-Addition)

4.3K
α,β-Unsaturated carbonyl compounds with two electrophilic sites, the carbonyl carbon, and the β carbon, are susceptible to nucleophilic attack via two modes: conjugate or 1,4-addition and direct or 1,2-addition.
Conjugate addition results in a thermodynamically stable product. The reaction retains the stronger C=O bond at the expense of the weaker C=C π bond. The process is slow as the β carbon is less electrophilic than the carbonyl carbon.
Direct addition products are...
4.3K
Regulation of Sodium and Potassium01:26

Regulation of Sodium and Potassium

2.3K
The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
2.3K
Bioavailability: Overview01:17

Bioavailability: Overview

428
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
428
Bioavailability: Overview01:13

Bioavailability: Overview

4.4K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.4K
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

340
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
340
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

210
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
210

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dietetic Management of Hyperkalemia in Chronic Kidney Disease: An International Mixed-Methods Study with Practice-Informed Recommendations.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·2026
Same author

Quality-oriented diet therapy for chronic kidney disease.

Nature reviews. Nephrology·2026
Same author

The Accuracy of Potassium Content on Food Labels in Canada.

Nutrients·2025
Same author

ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives.

Journal of the American Society of Nephrology : JASN·2025
Same author

Ultra-Processed Foods and Food Additives in CKD: Unveiling Hidden Risks and Advocating Smarter Food Choices.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

The Importance of Validation in Nutrition Research.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·2025

Related Experiment Video

Updated: Jan 31, 2026

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability
06:34

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability

Published on: April 28, 2022

5.7K

Potassium Additives and Bioavailability: Are We Missing Something in Hyperkalemia Management?

Kelly Picard1

  • 1Northern Alberta Renal Program, Alberta Health Services, Edmonton, Alberta.

Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation
|December 24, 2018
PubMed
Summary

Managing chronic kidney disease (CKD) requires attention to diet. Patients with CKD should be aware that phosphorus and potassium additives in processed foods are more bioavailable and concentrated than in whole foods, impacting dietary management.

More Related Videos

Metal-free Synthesis of Ynones from Acyl Chlorides and Potassium Alkynyltrifluoroborate Salts
09:58

Metal-free Synthesis of Ynones from Acyl Chlorides and Potassium Alkynyltrifluoroborate Salts

Published on: February 24, 2015

11.7K
A Whole Cell Bioreporter Approach to Assess Transport and Bioavailability of Organic Contaminants in Water Unsaturated Systems
13:16

A Whole Cell Bioreporter Approach to Assess Transport and Bioavailability of Organic Contaminants in Water Unsaturated Systems

Published on: December 24, 2014

10.9K

Related Experiment Videos

Last Updated: Jan 31, 2026

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability
06:34

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability

Published on: April 28, 2022

5.7K
Metal-free Synthesis of Ynones from Acyl Chlorides and Potassium Alkynyltrifluoroborate Salts
09:58

Metal-free Synthesis of Ynones from Acyl Chlorides and Potassium Alkynyltrifluoroborate Salts

Published on: February 24, 2015

11.7K
A Whole Cell Bioreporter Approach to Assess Transport and Bioavailability of Organic Contaminants in Water Unsaturated Systems
13:16

A Whole Cell Bioreporter Approach to Assess Transport and Bioavailability of Organic Contaminants in Water Unsaturated Systems

Published on: December 24, 2014

10.9K

Area of Science:

  • Nephrology
  • Nutritional Science
  • Food Chemistry

Background:

  • Hyperkalemia and hyperphosphatemia are prevalent in chronic kidney disease (CKD).
  • Dietary management for CKD often involves restricting potassium and phosphorus intake.
  • Processed foods contain higher concentrations of phosphorus and potassium, often from additives.

Purpose of the Study:

  • To highlight the increased bioavailability and concentration of phosphorus and potassium additives in processed foods.
  • To emphasize the need for updated dietary guidance for CKD patients regarding food additives.
  • To ensure the effectiveness and safety of dietary recommendations for managing hyperkalemia and hyperphosphatemia in CKD.

Main Methods:

  • Review of current literature on phosphorus and potassium content in processed versus whole foods.
  • Analysis of the bioavailability of phosphorus and potassium from food additives compared to natural food sources.
  • Evaluation of the implications for dietary teaching in chronic kidney disease management.

Main Results:

  • Phosphorus additives in processed foods are more bioavailable and concentrated than naturally occurring phosphorus.
  • Potassium additives are increasingly used in processed foods, leading to significantly higher potassium concentrations.
  • Potassium additives demonstrate greater bioavailability than naturally occurring potassium, similar to phosphates.

Conclusions:

  • Clinicians must educate CKD patients about the risks associated with phosphorus and potassium additives in processed foods.
  • Dietary recommendations for CKD need to account for the higher bioavailability and concentration of additives.
  • Awareness of these food source changes is crucial for safe and effective dietary management of CKD.